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Abstract
Background:  The underlying genetic alterations for squamous cell carcinoma (SCC) and
adenocarcinoma (AC) carcinogenesis are largely unknown.
Methods: High-resolution array- CGH was performed to identify the differences in the patterns
of genomic imbalances between SCC and AC of non-small cell lung cancer (NSCLC).
Results: On a genome-wide profile, SCCs showed higher frequency of gains than ACs (p = 0.067).
More specifically, statistically significant differences were observed across the histologic subtypes
for gains at 2q14.2, 3q26.2–q29, 12p13.2–p13.33, and 19p13.3, as well as losses at 3p26.2–p26.3,
16p13.11, and 17p11.2 in SCC, and gains at 7q22.1 and losses at 15q22.2–q25.2 occurred in AC (P
< 0.05). The most striking difference between SCC and AC was gains at the 3q26.2–q29, occurring
in 86% (19/22) of SCCs, but in only 21% (3/14) of ACs. Many significant genes at the 3q26.2–q29
regions previously linked to a specific histology, such as EVI1,MDS1, PIK3CA and TP73L, were
observed in SCC (P < 0.05). In addition, we identified the following possible target genes (> 30% of
patients) at 3q26.2–q29: LOC389174 (3q26.2),KCNMB3 (3q26.32),EPHB3 (3q27.1), MASP1 and SST
(3q27.3),  LPP  and  FGF12  (3q28), and OPA1,KIAA022,LOC220729,  LOC440996,LOC440997, and
LOC440998 (3q29), all of which were significantly targeted in SCC (P < 0.05). Among these same
genes, high-level amplifications were detected for the gene, EPHB3, at 3q27.1, and MASP1 and SST,
at 3q27.3 (18, 18, and 14%, respectively). Quantitative real time PCR demonstrated array CGH
detected potential candidate genes that were over expressed in SCCs.
Conclusion:  Using whole-genome array CGH, we have successfully identified significant
differences and unique information of chromosomal signatures prevalent between the SCC and AC
subtypes of NSCLC. The newly identified candidate target genes may prove to be highly attractive
candidate molecular markers for the classification of NSCLC histologic subtypes, and could
potentially contribute to the pathogenesis of the squamous cell carcinoma of the lung.
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Background
Lung cancer is responsible for the highest cancer-related
morbidity and mortality worldwide [1]. Non-small cell
lung cancer (NSCLC) comprises approximately 80% of all
lung cancers; squamous cell carcinoma (SCC) and adeno-
carcinoma (AC) are the two most common subtypes of
NSCLC [2]. Cumulative information suggests that the
SCC and AC subtypes' progress through different carcino-
genic pathways [2-4], but the genetic aberrations promot-
ing such differences, especially for the molecular
difference between two subtypes, remain unclear.
The most prevalent known chromosomal changes in
NSCLC include gains/amplifications at 3q, 5p, 7p, and
8q, and losses at 3p, 8p, 9p, 13q, and 17p [5-7]. Many sig-
nificant genes that map to these regions had previously
been associated with specific histologies [2-5]. Gains of
3q, 7p, 12p, and 20q, as well as losses of 2q, 3p, 16p, and
17p, are more frequently detected in SCC, whereas gains
of 1q and 6p as well as losses of 9q and 10p are more prev-
alent in AC [7-10]. One of the most prevalent and signifi-
cant differences between SCC and AC, a gain at the
chromosome 3q location, has been recognized in several
molecular cytogenetic studies [3-5]. Emerging data sug-
gests that regions of amplification of 3q have a profound
effect on tumor development and house candidate
biomarkers of disease progression, response to therapy,
and prognosis of SCC [11]. These findings suggest that
genes located at these chromosomal regions progress
through differing pathogenic pathways, but the genetic
aberrations promoting such differences are largely
unknown.
Array CGH has been recognized as a successful and valua-
ble tool for evaluation of the whole genome, as well as sig-
nificant genetic information at the single gene level, and
has enabled us to classify different neoplasm's based on
characteristic genetic patterns [12]. It has been used exten-
sively to study various human solid tumors including
NSCLC [13-15]. Although, recurrent genetic alterations in
NSCLC have been studied extensively, to our knowledge,
only a few studies have been performed to date to corre-
late the molecular difference between histologic subtypes
of NSCLC using high-resolution microarray CGH. There-
fore, further investigations are needed to gain additional
insight into the clinical significance of recurrent chromo-
somal alterations between the two subtypes of NSCLC.
In this study, therefore, we performed high-resolution
array-CGH to compare the different patterns of genetics
alterations, and to identify potential candidate genes that
may be associated with phenotypic properties that differ-
entiate early stage SCC from AC.
Methods
Tumor Samples and DNA Extraction
Twenty two SCCs and 14 ACs of the lung patients under-
going surgery as a primary treatment, without previous
radiation or chemotherapy, were analyzed. This study has
been reviewed and approved by the Institutional Review
Board of the Chungnam National University Hospital. All
cases were reviewed by pathologists to verify the original
histopathological diagnosis, depth of tumor, invasion,
tumor differentiation and lymph node metastasis. The
written informed consent was obtained from each patient
according to institutional regulations. The demographic
and pathological data, including age, gender and the
tumor stage were obtained by a review of the medical
records. All of the patients were classified according to the
WHO histologic typing of lung carcinomas and the UICC
TNM (tumor-node-metastasis) staging system. Some of
these samples were previously profiled for copy number
variations [15].
Tumor preparations were performed as described previ-
ously [7]. DNA isolation was performed following the
manufacturer's instructions (Promega, Madison, WI,
USA), with some modifications as described before
[15,16]: commercial genomic DNA was used as a refer-
ence (Human Genomic DNA: Female; Promega Corpora-
tion, Madison, WI; Cat. No. G1521).
Contraction of BAC clones mediated array CGH 
microarray
The characteristics of the MacArray™ Karyo4000 chips
(Macrogen, Inc., Seoul) [17-20] were used in this study
consist of 4,046 human BACs, which were applied in
duplicate and a resolution of 1 Mbp http://www.macro
gen.co.kr. BAC clones were selected from the proprietary
BAC library of Macrogen, Inc. All clones were two-end
sequenced using an ABI PRISM 3700 DNA Analyzer
(Applied Biosystems, Foster City, CA), and their
sequences were blasted (using BLAST; http://
blast.ncbi.nlm.nih.gov/Blast.cgi)) and mapped according
to their positions, as described in the University of Cali-
fornia, Santa Cruz (UCSC) human genome database
http://www.genome.ucsc.edu (Build 36, Version Mar.
2006 (hg18)). Locus specificities of chosen clones were
confirmed by removing multiple loci-binding clones indi-
vidually under standard fluorescence in situ hybridization
(FISH) [21]. These clones were prepared using the con-
ventional alkaline lysis method to obtain BAC DNA. The
arrays were manufactured using an OmniGrid arrayer
(GeneMachine, San Carlos, CA) using a 24-pin format.
Each BAC clone was represented on an array as triplicate
spots and each array was pre-scanned using a GenePix
4200A scanner (Axon Instruments, Foster City, CA) for
proper spot morphology.BMC Cancer 2009, 9:237 http://www.biomedcentral.com/1471-2407/9/237
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Array CGH experiment
Array CGH was performed as described previously [15].
Briefly, arrays were pre-hybridized with salmon sperm
DNA to block repetitive sequences in the BACs. 500 ng of
normal male DNA (reference) and digested tumor DNA
(test) were labeled with Cy5-dCTP and Cy3-dCTP, respec-
tively, by randomly primed labeling (Array CGH
Genomic Labeling System; Invitrogen, CA, USA). The
labeled probe and human Cot-I DNA were mixed and dis-
solved in hybridization solution. Hybridizations were
performed in a sealed chamber for 48 h at 37°C. After
hybridization, array slides were scanned on a GenePix
4200A two-color fluorescent scanner (Axon Instruments,
Union City, CA, USA); quantification was performed
using GenePix software (Axon Instruments).
Analyzed BAC clones
After scanning, the fluorescent intensities of the red and
green channels were saved as two TIFF image files and the
background was subtracted from these. Log2-transformed
fluorescence ratios were calculated from background-sub-
tracted median intensity values, and these ratios were
used for normalization using intensity normalization
methods. To adjust for effects due to variation between
the red and green dyes, LOWESS normalization was
applied. Then, the ratio of the red/green channel of each
clone was calculated and log2 transformed. Spot quality
criteria were set as foreground to background greater than
3.0 and standard deviation of triplicates less than 0.2. The
breakpoint detection and status assignment of genomic
regions is performed by the GLAD software was used [22].
The total number of 3,776 BAC clones was analyzed
excluding the 31 missing values and sex chromosomes
(238) since female tumor DNA was hybridized with male
control DNA to serve as an internal control. A low-level
copy number gain was defined as a log 2 ratio > 0.25 and
a copy number loss was defined as a log 2 ratio <-0.25.
High-level amplification of clones was defined when their
intensity ratios were higher than 0.8 in log2 scale and vice
versa for homozygous deletion [23-25]. This threshold
value was defined empirically as a value 3-fold that of the
standard deviation calculated from 30 normal male to
normal females in hybridization experiments. Macrogen's
MAC viewer v1.6.6, CGH- explorer 2.55, and avadis 3.3
prophetic were used for graphical illustration and image
analysis of array CGH data.
Statistical analysis for array CGH
For group comparison, the differences in log2 ratios, as
well as the Fisher exact test were used to determine
whether there was any significant gain or loss of genomic
content within particular cytobands with cancer type. The
Fisher exact test utilized two categories normal and abnor-
mal (loss and gain), with the null hypothesis that the rel-
ative proportions of each of the two imbalance categories
would be expected to be the same in the groups. The
counts of abnormal versus normal were summarized by
subtype of NSCLC (SCC and AC)for each BAC, providing
2 × 2 tables for analysis. A multiple testing correction
(Benjamini-Hochberg false discovery rate (FDR)) applied
to correct for the high number of false positive calls. The
R 2.2.1 package of the Bioconductor Project http://
www.bioconductor.org was used for detection of the fre-
quency of gain or loss and statistical analysis. Macrogen's
MAC viewer v1.6.6, CGH- explorer 2.55, and avadis 3.3
prophetic were used for graphical illustration and image
analysis of array CGH data.
Quantitative Real-time PCR analysis
Real-time quantitative PCR analysis was performed using
the ABI PRISM 7900HT Sequence Detection system and
TaqMan Gene Expression assays according to the manu-
facturer's instructions (Applied Biosystems, Foster city,
CA). In brief, samples (2.5% of the reverse transcription
reaction) were amplified using the Universal Master Mix
(Applied Biosystems) and cycling conditions of 15 s of
denaturating time (95°C) and 1 min of annealing/ampli-
fication time (60°C) for 40 cycles after an initial activa-
tion step of 10 min at 95°C. All samples were assayed in
triplicates. To enable detection of possible contaminating
genomic DNA, we analyzed non-reversed transcribed
total RNA from all tumors in parallel with the cDNAs.
Normalized normal human pooled genomic DNAs
(Promega, Madison, WI, USA) were used as reference
DNAs. All data analysis was used ArrayAssist® (Stratagene,
La Jolla, USA) and R (Ver.2.7.2). Correlation between
BAC chip and Q RT-PCR data was performed by Pearson
correlation analysis (P < 0.05).
Results
Array CGH analysis in SCCs and ACs of the lung
One-megabase through put whole genome array-CGH
was performed to establish distinct differences in chromo-
somal copy number changes between the SCC and AC his-
tologic subtypes of NSCLC. Clinicopathological data for
the 22 SCCs and 14 ACs patients are summarized in Table
1. All of the NSCLC patients (100%) had copy number
aberrations and each patient evidenced numerous copy
number changes. On average, 173 clones were gained
(range, 14–579), and 136 clones were lost (range, 5–537)
per patient. Although the difference in the copy number
gain, between the two histologic subtypes was not statisti-
cally significant, we found higher frequency of gains in
SCC compared to AC (203 vs. 125, respectively, P  =
0.067). To visualize both common and specific altered
chromosomal regions in each subtype of NSCLC, signal
intensity ratios for each spotted BAC clones were calcu-
lated and displayed as log2 plots (Figures 1 and 2). Most
of the chromosomes in this profile showed multiple seg-BMC Cancer 2009, 9:237 http://www.biomedcentral.com/1471-2407/9/237
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mental alterations, including single copy as well as high
level gains and losses.
Distinct genomic signatures between SCC and AC 
histologic subtypes
Across the whole genome, we identified specific genomic
alterations between the two subtypes. Gains at 2q, 3q,
12p, and 19p, as well as losses at 3p, 4p, 16p, and 17p
were found specific to SCC, whereas gains at 6p and 7q
and losses at 4q and 15q were more prevalent in AC. A
summary of preferentially gained and lost genomic
changes for patients with SCC and AC are listed in Table 2
(> 30% of patients). More specifically, statistically signifi-
cant differences were observed across the histologic sub-
types. We identified significant chromosomal regions
between the two subtypes for gains of 2q14.2, 3q26.2–
q29, 12p13.2–p13.33, and 19p13.3, as well as losses of
3p26.2–p26.3, 16p13.11, and 17p11 in SCC (P < 0.05),
and a gain of 7q22.1 and losses of 15q22.2–q25.2 in AC
(P < 0.05). The statistically significant genomic regions
preferentially gained and lost by histologic subtypes and
the potential target genes are summarized in Table 3 and
Figure 3 (see Additional file 1).
Significant differences were not reached for gains at 3q29
(LMLN, LOC348840,LOC442100, and BDH; P = 0.085) or
losses at 3p25.1 (ZFYVE20 and LOC344875; P = 0.084),
3p26.1 (GRM7; P = 0.084), 3p26.3 (CHL1; P = 0.084) and
4p16.1 (WFS and PPP2R2C; P = 0.084) in the SCC series,
and gains at 6p25.3 (LOC44118;  P  = 0.065), 7q21.11
(CD36;  P  = 0.069), 7q32.1 (SND1;  P  = 0.069), 7q34
(EPHB6, TRPV6, TRPV5, C7orf34 and KEL; P = 0.069) or
losses at 4q13.3 (ADAMTS3; P = 0.069) in the AC group;
however, all had borderline significances (data not
shown).
Significant copy number differences of target genes at 
3q26.2–q29 between SCC and AC
In this array profile, the most striking difference between
SCC and AC was gains at 3q26.2–q29, with 19 of 22
patients showing gains in at least part of these chromo-
somal regions (86%) in SCCs, but only 21% (3/14) were
observed in ACs. Several putative cancer-related genes at
the 3q26.2–q29 regions were previously linked to specific
histologic subtypes; specifically, gains at EVI1 and MDS1
(3q26.2),PIK3CA (3q26.32), and TP73L (3q28) were sig-
nificantly observed in SCCs (P < 0.05). Additionally, we
identified possible candidate target genes in these chro-
mosomal regions, that are not yet known for their
involvement in the pathogenesis of SCC (> 30% of
patients): namely, LOC389174  (3q26.2),KCNMB3
(3q26.32),EPHB3  (3q27.1),  MASP1  and  SST  (3q27.3),
LPP  and  FGF12  (3q28), and OPA1, KIAA022,
LOC220729, LOC440996, LOC440997 and LOC440998
(3q29), all of which were significantly targeted in SCC (P
< 0.05). A representative high level amplification
observed recurrently at 3q27 (MCF2L2 and B3GNT5) in
AC (A), and an example of an individual profile of high
level amplifications around the 3q26.1–q28 regions in
SCC (B) is presented in Figure 4.
Among these significantly associated genes at 3q26–q29
in SCC, high-level amplifications were detected for the
genes,  EVI1  and MDSI  at 3q26.2 (23 and 5%, respec-
tively), and EPHB3,MASP1, and SST at 3q27.1–q27.3 (18,
18, and 9%, respectively). For this analysis, we defined a
high level amplification as log2 signal intensity ratio
reaching +0.8.
Table 1: Summary of clinico pathological data of the samples
TNM classification
No Gender Age Histology Lymph node status Tumor stage
1 M 61 AC Absent IB
2 F 50 AC Present IIIA
3 F 47 AC Absent IB
4 M 66 AC Absent IA
5 M 65 AC Present IIIA
6 F 61 AC Absent IA
7 F 56 AC Present IIB
8 M 72 AC Absent IA
9 M 61 AC Present IIB
10 F 70 AC Present IIIA
11 M 60 AC Present IIIA
12 M 70 AC Present IIB
13 M 75 AC Present IIIA
14 F 69 AC Absent IA
15 M 67 SCC Present IIA
16 M 51 SCC Present IIIA
17 M 59 SCC Absent IB
18 M 69 SCC Absent IB
19 M 62 SCC Absent IA
20 F 72 SCC Absent IB
21 M 60 SCC Present IIIA
22 M 64 SCC Absent IB
23 M 65 SCC Absent IB
24 M 65 SCC Present IIB
25 M 64 SCC Present IIB
26 M 65 SCC Present IIB
27 M 64 SCC Absent IB
28 M 64 SCC Absent IB
29 M 66 SCC Present IIIA
30 M 74 SCC Absent IB
31 F 72 SCC Absent IA
32 M 74 SCC Absent IB
33 M 69 SCC Absent IB
34 M 55 SCC Present IIIA
35 M 90 SCC Present IIB
36 F 69 SCC Absent IABMC Cancer 2009, 9:237 http://www.biomedcentral.com/1471-2407/9/237
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The X-axis represents chromosome number (1 – 22) and the Y-axis represents the genome-wide frequencies of gains (> 0.25  of intensity ratio) and losses (< 0.25 of intensity ratio) for each clone of NSCLC are shown Figure 1
The X-axis represents chromosome number (1 – 22) and the Y-axis represents the genome-wide frequencies 
of gains (> 0.25 of intensity ratio) and losses (< 0.25 of intensity ratio) for each clone of NSCLC are shown. Ver-
tical lines indicate chromosomal boundaries. (A) Frequencies of genes increased in copy number or decreased in copy number 
in SCC of the lung. (B) Frequency of gene copy number abnormalities in the AC. Gains and losses are shown as green and red 
color bars, respectively, which indicate the overall chromosomal copy number aberrations detected.
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As a gain of EVI1 and MDSI at 3q26.2 has been described
previously in SCC, we sought to determine whether there
exist any correlations between EVI1  or  MDSI  and the
newly amplified genes of EPHB3, MASP1, or SST. Interest-
ingly, co-amplifications were demonstrated for EVI1 and
EPHB3 in 18% and for EVI1 and SST in 14%. All of the
amplified genes, including significantly associated targets
in SCC at the 3q26.2–q29 regions, are summarized in
Table 4. Figure 5A shows a weighted frequency (%) dia-
gram for chromosome 3 with high-level amplifications,
and Figure 5B represents more detailed profiles at the
3q26.2–q29 regions with the significantly associated
genes in SCC. The data discussed in this publication have
been deposited in NCBIs Gene Expression Omnibus
(GEO) and are accessible through GEO Series accession
number GSE 16597 http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE16597.
Real Time quantitative PCR analysis
To validate the consequences of gene amplification by
array CGH, we performed subsequently real-time quanti-
tative PCR analyses for three potential oncogenes (EPHB3,
MASP1, or SST) at 3q27.1–q27.3. Primers for the three
genes (EPHB3, MASP1, or SST) are presented in Table 5.
Although the absolute values of selected genes were differ-
ent between two analyses, significant correlations were
observed between two data sets (P < 0.05). The value of
array CGH was depicted by linear-ratios and N-value was
delineated in real time PCR. Correlation coefficients
Signal intensity ratios for each spotted BAC clones of SCCs and ACs displayed as log2 plots Figure 2
Signal intensity ratios for each spotted BAC clones of SCCs and ACs displayed as log2 plots. A total of 4,046 BAC 
clones were ordered (x-axis) according to the map positions and the chromosomal order from 1pter to 22qter.
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between gene expression levels in real time PCR and array
CGH analysis for three genes (EPHB3, MASP1, or SST)
were 0.694, 0.723 and 0.752, respectively. Figure 6A
shows a comparison of mean relative expression levels for
EPHB3, MASP1, or SST genes between array CGH and real
time PCR results in NSCLCs and three cases with amplifi-
cation at 3q27.1–q31.3 are shown in Figure 6C. Moreo-
ver, real time PCR analysis demonstrated higher
expression levels for EPHB3, MASP1, and SST genes in
SCCs compare to ACs. This corresponds are shown in Fig-
ure 6B.
Discussion
Non-small cell lung cancer is the most frequently occur-
ring type of lung cancer, with SCC and AC being the two
main subtypes [12]. Since the most common genetic aber-
rations in NSCLC had already been identified in our pre-
vious study [15], we paid attention to explore candidate
genes that may be associated with phenotypic properties
that differentiate early stages SCC from AC. A whole
genomic strategy allowed us to define candidate regions
that may contain specific cancer-related genes involved in
early stages of SCC and AC.
Gains of 2q, 3q, 12p, and 19p, as well as losses of 3p, 4p,
16p, and 17p, were found to be specific to SCC, whereas
gains of 6p and 7q and losses of 4q and 15q were more
prevalent in AC. More specifically, statistically significant
differences were observed between the two subtypes for
gains at 2q14.2, 3q26.2–q29, 12p13.2–p13.33, and
19p13.3, as well as losses at 3p26.2–p26.3, 16p13.11 and
17p11.2 in SCCs, whereas gains at 7q22.1 and losses at
15q22.2–q25.2 were observed in ACs (P < 0.05). These
findings support the notion that the two histologic sub-
types progress through different pathogenic pathways and
further indicate that SCC and AC can be readily distin-
guished from each other at the chromosomal level.
Table 2: Summary of histology-enriched chromosomal alterations by array CGH analysis
Chromosomal alterations Histology
Squamous cell carcinomas Adenocarcinomas
Gained regions 1p36.33-1q44 1p36.33-1q44
2q14.2 5p13.2–5p15.33
3q13.12–3q29 6p25.3
5p12–5p15.33 7q22.1–7q36.3
7p12.2–p22.3 16p13.3
9q34.3 17q21.2–17q25.3
10q26.3 20q13.33
11p13.3-11q15.5
12p11.1-12q24.33
13q21.1–13q34
15q22.2–q26.3
16p13.3-16q24.3
17q23.2–17q25.3
19p13.3–19q12
20q13.33
Lost regions 1p21.1–1p36.33 1q21.1
2q37.1 4q13.3
3p12.2–3p26.3 5q13.2
4p12–p16.1 8p12–8p23.3
5q11.2–5q35.1 13q12.11–13q21.1
8p21.2–8p23.3 14q32.33
9p12–p13.1 15q11.2–15q25.3
10q11.22–10q26.3 18q21.2
13q12.11–13q14.3 19q13.2–19q13.31
14q32.33 20p11.23
16p12.3–16p13.11 21q11.2
17p11.2–17p13.3 22q11.1
18q12.3–18q23
20p11.23
21q11.2
22q11.1BMC Cancer 2009, 9:237 http://www.biomedcentral.com/1471-2407/9/237
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Although, these findings are similar to the findings
reported in previous studies [26-29], four chromosomal
regions for gains at 2q14.2 or 19p13.3 in SCC, and gains
at 7q22.1 or losses at 15q22.2–q25.2 in AC, have not been
described as focal regions of lung cancer.
We found 55% of copy number gains at the 2q14 region
in SCCs, but only 7% of gains were detected in ACs (P =
0.046). Although, little is known about gains at chromo-
some 2q14, the genomic region containing this region
may harbor potential oncogenes involved in the tumori-
genesis of SCC. Future studies will be needed to verify the
significances of this outcome.
A gain at 19p13.3 was observed in 41% of SCCs, whereas
no gains in ACs (P = 0.008), which harbored the genes
SHC2,C19orf19,MADCAM1,C19orf20,CDC34,  GZMM,
and  BSG. Emerging data [30] have described that the
C19orf19 gene product is EGFR-associated and phosphor-
ylated at 5 tyrosines in response to EGFR activation and,
therefore, represents a new component of the EGFR sign-
aling network. The over expression of the EGFR gene in
SCC has been well recognized in several molecular cytoge-
netic studies [8,31,32]. Although no significant correla-
tion was found regarding the association between EGFR
and  C19orf19  in this study (data not shown), further
investigations will enable us to determine the functional
associations of these two genes, and whether these genes
or additional genes at 19p13.3 contribute to the genome
differentiating SCC from AC.
The present study revealed that gain of 7q22.1 is more
specific for lung AC than for SCC (P = 0.023). This region
detected as an 89-kbp gene-specific copy number gain,
entered at TRRAP,ZKSCAN1,ZNF38  and  ZNF3. Louko-
poulos et al. [33] recently showed that the frequent ampli-
Table 3: BAC clones with significant frequency differences between SCC and AC subtypes of NSCLC
BAC clone Regions Gene contained in clones % of gain in SCCs‡ % of gain in AC† p-value*
Gains¶
BAC13_I04 2q14.2 55 70 . 0 4 6
BAC215_M07 3q26.2 EVI1 77 29 0.007
BAC28_H10 3q26.2 MDS1 45 70 . 0 3 4
BAC127_C12 3q26.32 PIK3CA, KCNMB3 50 14 0.050
BAC78_P09 3q26.2 LOC389174 45 70 . 0 3 4
BAC97_L20 3q27.1 EPHB3 32 00 . 0 3 9
BAC187_G13 3q27.3 MASP1 45 70 . 0 3 4
BAC195_F06 3q27.3 SST 32 00 . 0 3 9
BAC62_G09 3q28 64 70 . 0 0 2
BAC29_O18 3q28 TP73L 45 70 . 0 3 4
BAC74_E06 3q28 50 70 . 0 1 5
BAC143_F11 3q28 FGF12 45 70 . 0 3 4
BAC144_N20 3q28 LPP 48 00 . 0 3 2
BAC95_M19 3q29 OPA1 55 70 . 0 4 6
BAC96_C05 3q29 KIAA0226, LOC220729, LOC440996, LOC440997, LOC440998 45 70 . 0 3 4
BAC42_D19 7q22.1 TRRAP 0 29 0.023
BAC141_P01 7q22.1 ZKSCAN1, ZNF38, ZNF3 0 29 0.023
BAC118_C23 12p13.2 CDKN1B, DKFZP434F0318 50 00 . 0 0 3
BAC26_P09 12p13.32 TSPAN9, LOC399986, LOC441627 59 70 . 0 0 1
BAC159_B18 12p13.33 LOC440123, SLC6A12, SLC6A13 45 00 . 0 0 2
BAC179_J19 12p13.33 SLC6A12, SLC6A13 32 00 . 0 0 3
BAC18_B14 19p13.3 SCHC2, C19orf19, MADCAM1,
C19orf20, CDC34, GZMM, BSG
41 00 . 0 0 8
Losses§
BAC83_J18 3p26.2 LOC440943 36 00 . 0 1 8
BAC229_D19 3p26.3 CCR2, CCRL2, APOD 45 00 . 0 0 5
BAC57_A15 15q22.2 RORA 5 36 0.033
BAC175_C05 15q25.2 DNM1DN11-6, LOC388160, LOC440300, LOC388152, LOC161527, 
LOC440301, LOC159170
5 36 0.033
BAC169_L10 16p13.11 55 70 . 0 4 6
BAC130_G23 17p11.2 64 36 0.039
Abbreviations: †AC, Adenocarcinoma; ‡SCC, Squamous cell carcinoma; * P values from Fisher's exact test on categorized log2 ratio values. 
¶Alterations were defined by log2 ratio thresholds of 0.25 for copy number gain. Using this threshold, we generated a frequency table. §Alterations 
were defined by log2 ratio thresholds of – 0.25 for copy number loss. Using this threshold, we generated a frequency table.BMC Cancer 2009, 9:237 http://www.biomedcentral.com/1471-2407/9/237
Page 9 of 15
(page number not for citation purposes)
fication of the TRRAP gene in AC from the pancreas, and
another study using array-CGH reported high level ampli-
fications at 7q21–q22 in gastric ACs [34]. Taken together,
these results and our own results suggest that this region
might be affected in tumorigenesis of AC.
Chromosome 15q was detected in 36% of copy number
losses with 15q22.2–q25.2 in the AC group, whereas only
5% of loss were detected in SCC (P  = 0.033). These
regions have not been described as a common change in
AC of the lung thus far, but are commonly found in ACs
from follicular and clear cell AC. Roque et al. [35] demon-
strated that 15q loss was significantly associated with fol-
licular adenocarcinomas, and Okada et al. [36] reported
that the loss of heterozygosity (LOH) at 15q was detected
in at least 50% of clear cell ACs, indicating that these can-
didate regions may contain specific cancer related genes
involved in AC. Future work will validate of these find-
ings.
In this array survey, the most salient discriminators
between SCC and AC were gains at 3q26.2–q29, occurring
in 86% of SCCs, whereas only 21% were observed in ACs.
Furthermore, high-level amplifications in these regions
were more prevalent in SCCs than ACs (6/22 = 27% vs. 1/
14 = 7%, respectively). Our data also pointed out that 4 of
6 (67%) high level amplifications at 3q26.2–q29 regions
were detected in stage (I+IIA) SCCs without lymph node
metastatic lesions. It is very interesting to note that the
high level amplifications at 3q26.2–q29 were more prev-
alent in stage (I+IIA) SCCs than more advanced stages.
Heselmeyer et al. [37,38] reported that gain of chromo-
some 3q could be found in early dysplasic lesions as well
as in invasive cervical cancer, but at a reduced frequency
in advanced stages of disease. Furthermore, Yen el al. [39]
described that the high-level amplifications on 3q25.3-
qter were all found in stage IB tumors in esophageal squa-
mous cell carcinoma. By combining results of this study
with other reports, it is very likely that amplification of
genes located on 3q may occur in early stages in the can-
cer. One possible explanation is that the alterations of
The statistically significant genomic regions preferentially gained and lost between SCC and AC of NSCLC patients Figure 3
The statistically significant genomic regions preferentially gained and lost between SCC and AC of NSCLC 
patients. Significant genomic regions between SCC and AC of NSCLC represent in the x-axis and the percentage of gains 
(upper panel) and losses (lower panel) expressed regions in each chromosomal regions is illustrated to the y-axis (red bars 
represent the SCC and green bars represent ACs).
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Individual profiles of high copy number changes at 3q Figure 4
Individual profiles of high copy number changes at 3q. A. High-level amplifications on 3q27 for AC from patient 12, B. 
3q26.2–q28 for SCC from patient 27. In the intensity ratio profiles, the x-axis represents the map position of corresponding 
clone and the intensity ratios were assigned to the y-axis. The schematic presentation of cytogenetic bands as well as a map 
position is shown below the plot.
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Table 4: High-level amplifications at 3q26.2–q29 by array CGH analysis in NSCLC, together with candidate genes
BAC clone Chromosome location Gene contained in clones % of case of amplifications
SCC‡
BAC215_M07 3q26.2 EVI1 23 (5/22)
BAC28_H10 3q26.2 MDSI 5 (1/22)
BAC130_O18 3q26.31 NAALADL2, 9 (2/22)
BAC1_N14 3q26.32 9 (2/22)
BAC231_I11 3q26.33 LOC401102, 14 (5/22)
3q27.1 EPHB3, 18 (4/22)
BAC187_G13 3q27.3 MASP1 18 (4/22)
BAC179_E01 3q27.3 BCL6, LOC389185 14 (3/22)
BAC195_F06 3q27.3 SST 14 (3/22)
BAC74_E06 3q28 CLDN1, 9 (2/22)
BAC144_N20 3q28 LPP 9 (2/22)
AC†
BAC176_G15 3q27.1 MCF2L2, B3GNT5 7 (1/14)
Abbreviations: Abbreviations: ‡SCC, Squamous cell carcinoma; †AC, Adenocarcinoma.BMC Cancer 2009, 9:237 http://www.biomedcentral.com/1471-2407/9/237
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(A) Weighted frequency (%) diagram for chromosome 3 with high-level amplifications Figure 5
(A) Weighted frequency (%) diagram for chromosome 3 with high-level amplifications. In the intensity ratio pro-
files, the x-axis represents the map position of the corresponding clone and the intensity ratios were assigned to the y-axis. (B) 
More detailed profile on 3q26.2–q29 with the significantly associated genes in the SCC. The schematic presentation of cytoge-
netic bands as well as a map position is shown below the plot.
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Table 5: Primers used for Real-time quantitative PCR analysis
Gene name Chromosome
location
Primer forward Primer reverse
EPHB3 3q27.1 GGGTCAGAACCTTCCCTAAAGTG GTTAAAGATACCCCAAATAAGTACTGCCT
MASP1 3q27.3 CCTTGCAAGATGAGGGAGTTCAG GCCCCTATACTCTTCCTTCCTATGT
SST 3q27.3 TGACCGACTGCGCTTATCATG TCCCGAAGCTCTTGAGAAAACTATC
(A) The scatter plot analysis of all data points of three genes (EPHB3, MASP1 and SST) by Array CGH (X axis) and Q-RT-PCR  (Y axis) analysis in NSCLC patients Figure 6
(A) The scatter plot analysis of all data points of three genes (EPHB3, MASP1 and SST) by Array CGH (X axis) 
and Q-RT-PCR (Y axis) analysis in NSCLC patients. Each dark square, the log2 ratio value of the clone containing one of 
these genes for one case. The correlation coefficients (r) and P-value are given in the upper left corner of the figure. (B) Com-
parison of real time PCR analysis of EPHB3, MASP1, or SST between SCCs and ACs. Note that the mean expression levels for 
selected genes were higher in SCCs compared to ACs. (C) Gene expression levels in Q RT PCR of three genes in three cases 
seen with amplification at 3q27.1–q27.3 by Array CGH. Each samples are depicted (x-axis) and the fold difference of array 
CGH was depicted by linear-ratios, and N-value was delineated in real time PCR (y-axis). The heights of the bars represent 
mean expression level of the indicated genes in each SCC cases.
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genes are no longer necessary for maintenance of cancer
cells survival [40]. Further studies are needed to confirm
this hypothesis.
Previous analyses of the NSCLC genome with low-resolu-
tion chromosomal or BAC array-CGH have consistently
demonstrated genome differentiation between SCC and
AC in the telomeric subregion, 3q26-qter [40-43]. Several
interesting cancer-related genes located in these genomic
alteration regions have previously been identified with
specific histologies, such as EVI1 (ecotropic viral integra-
tion site 1) and MDS1 (myelodysplastic syndrome 1) at
3q26.2,PIK3CA  (phosphoinositide-3-kinase, catalytic,
alpha polypeptide) at 3q26.32, and TP73L (tumor protein
p73-like) at 3q28 region [40,41]. In this array survey, we
sought to determine whether there exist additional candi-
date genes at 3q26-qter regions that drive genome differ-
entiation of SCC from AC subtypes of NSCLC, and we
were capable of detecting the following possible target
genes previously not assumed to play a pathogenic role in
SCC;  LOC389174  (3q26.2),KCNMB3  (3q26.32),EPHB3
(3q27.1),  MASP1  and  SST  (3q27.3),  LPP  and  FGF12
(3q28), and OPA1,KIAA022,  LOC220729,
LOC440996,LOC440997, and LOC440998 (3q29), all of
which were significantly targeted in SCC (P < 0.05). These
genes have not been described in squamous cell carci-
noma of the lung thus far, but are commonly found in
other cancers or cancer cell lines [40-44]. Lukashova-v
Zangen I el al. [43] described that the overexpression of
EPHB3  gene in ependymomas with high proliferation
indices was associated with a poor outcome, and Kuraya
el al. [45] demonstrated the high expression of MASP1
gene in glioma cell line. More strikingly, among these pos-
sible target genes within 3q26–q29 regions, EPHB3
(3q27.1), and MASP1 and SST (3q27.3) showed high-
level amplifications, in more than three patients each in
SCC, implicating that these genes may be major potential
targets for characterization of NSCLC histologic subtypes.
Real time PCR analysis demonstrated over expression
level for the three genes (EPHB3,  MASP1  and SST) in
SCCs compare to ACs. These results were in agreement
with array-CGH results.
Conclusion
The high-resolution analysis allowed us to propose novel
candidate target genes that may be associated with pheno-
typic properties that differentiate early stages of SCC from
AC. The newly identified candidate genes could be useful
biomarkers for the early detection and characterization of
NSCLC histological subtypes as well as novel targets for
therapeutic interventions of early stages of squamous cell
carcinoma of the lung.
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